Part 1 Introduction: renal scarring - a multi-organ approach to fibrosis, A.M. El Nahas. Part 2 Renal fibrosis: pathways to renal fibrosis, A.M. El Nahas; interstitial macrophages as mediators of renal fibrosis, A.A. Eddy; tissue inhibitor of the metalloproteinases and renal extracellular matrix accumulation, C.L. Jones et al; role of the macrophage in the development of glomerulosclerosis, K. Harris et al; matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases expression by tubular epithelia and interstitial fibroblasts in the normal kidney and in fibrosis, J.T. Norman. Part 2 Organ fibrosis: pathogenesis, experimental manipulation and treatment of liver fibrosis, M.J.P. Arthur; pathogenesis of lung fibrosis and potential new therapeutic strategies, R.J. McAnulty and G.J. Laurent; neointimal fibrosis in vascular pathologies - role of growth factors and metalloproteinases in vascular smooth muscle proliferation, A.C. Newby et al. Part 3 Renal extracellular matrix and fibroblasts: collagen turnover in renal disease, M. Costigan et al; glomerular cell proteoglycans - their possible role in progressive glomerular disease, M. Davies; human renal fibroblast cell lines (tFKIF and tNKF) are new tools to investigate pathophysiologic mechanisms of renal interstitial fibrosis, G.A. Mueller et al; myofibroblast differentiation during fibrosis, A. Desmouliere and G. Gabbiani; integrin distribution in normal kidney and cultured human glomerular cells, K.N. Stewart et al; transforming growth factor Beta (TGF-B) regulates the matrix-associated plasminogen activator inhibitor 1 (PAL-1) in glomerular mesangial and epithelial cells, H.M. Wilson et al; increased fibronectin incorporation into extracellular matrix in response to platelet-derived growth factor is mediated by transforming growth factor Beta, N.G. McKay. Part 4 Therapy: opportunities for the discovery of novel therapies for fibrotic diseases, T.J. Franklin.
